- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01747642
Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular carcinoma
To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib
To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib
To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib
To see if there is improved survival in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Dhaka, Bangladesh, 1215
- Recruiting
- Farabi General Hospital
-
Contact:
- Mamun A Mahtab, MD, FACG
- Phone Number: +8801711567275
- Email: shwapnil@agni.com
-
Contact:
- Helal Uddin, BSc
- Phone Number: +880-1819251514
- Email: crobangladesh@gmail.com
-
Principal Investigator:
- Mamun A Mahtab, MD, FACG
-
Sub-Investigator:
- Lovely Begum, BPharm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with HCC irrespective of etiology, age, gender and status of underlying liver disease.
- Patients with HCC who are not suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy.
- Patients with HCC who have evidence of tumor metastasis
- Patients with HCC who are voluntarily unwilling to take established modalities of treatment i.e. surgery and/or chemotherapy.
- Patients with HCC in whom all possible treatment options have been exhausted.
Exclusion Criteria:
- Patients with HCC who are suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy.
- Patients with HCC who have no evidence of tumor metastasis
- Patients with HCC who are willing to take established modalities of treatment i.e. surgery and/or chemotherapy.
- Patients with HCC who are voluntarily unwilling to be included in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Oncoxin
Syp Oncoxin 25 ml bd and Cap.
Oncoxin bd orally for 180 days
|
Syp Oncoxin 25 ml bd and Cap.
Oncoxin bd for 180 days
|
ACTIVE_COMPARATOR: Oncoxin & Suranix
Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap.
Oncoxin bd orally for 180 days
|
Syp Oncoxin 25 ml bd and Cap.
Oncoxin bd for 180 days
Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap.
Oncoxin bd for 180 days
Other Names:
|
NO_INTERVENTION: Supportive treatment
Only supportive treatment.
No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients who have prolonged survival
Time Frame: 24 weeks
|
To study the number of participants who have prolonged survival in months after receiving Oncoxin plus Surafenib for 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in serum alpha-fetoprotein level and decrease in tumor size
Time Frame: 24 weeks
|
To see whether Oncoxin plus Surafenib results in reduction in serum alpha-fetoprotein level in ng/ml and decrease in tumor size in mm in hepatocellular carcinoma patients off treatment for 24 weeks, after receiving Oncoxin plus Surafenib for 24 weeks.
|
24 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mamun A Mahtab, MD, FACG, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Sorafenib
Other Study ID Numbers
- OP2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaRecruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on Oncoxin
-
Catalysis SLCompleted
-
Clinical Research Organization, Dhaka, BangladeshUnknownHepatocellular CarcinomaBangladesh
-
Catalysis SLCompletedMucositis OralRussian Federation
-
Catalysis SLCompletedBreast Fibrocystic DiseaseCuba
-
Catalysis SLCompletedNon-small Cell Lung Cancer Stage III | Gastric Cancer Stage III | Gastric Cancer Stage II | Non-small Cell Lung Cancer Stage IIKazakhstan, Russian Federation
-
Catalysis SLCompletedCutaneous Melanoma, Stage II | Cutaneous Melanoma, Stage III | Malignant Cutaneous MelanomaCuba
-
Catalysis SLCompletedCervical Carcinoma Stage II | Cervical Carcinoma Stage III | Cervical Carcinoma Stage IV | Endometrial Adenocarcinoma Stage II | Endometrial Adenocarcinoma Stage III | Endometrial Adenocarcinoma Stage IVCuba